In summary, we describe for the first time dysregulation of the NLRP3 inflammasome in murine SD and demonstrate that IL-1β actively contributes to disease pathogenesis, suggesting that this pro-inflammatory cytokine may be a target for clinical intervention as a potential disease-modifying therapy in this currently intractable LSD. Here, IL1B is linked to Salla disease.